F.D.A. Approves a New Antipsychotic Drug

Published On Sep 26, 2024, 6:47 PM

The FDA has approved Cobenfy, the first new antipsychotic drug for schizophrenia in many years. Unlike existing treatments that block dopamine receptors, Cobenfy works by influencing acetylcholine levels, which may help address side effects like weight gain and lack of motivation that patients often experience. However, concerns remain regarding the long-term efficacy and potential side effects, as studies thus far have only lasted five weeks.

Read full article

Stock Forecasts

BMYView BMY chart on TradingView

Positive

Cobenfy could significantly improve treatment options for schizophrenia and potentially capture market share from existing drugs, particularly if it proves effective in the long term. Its novel approach may lead to better patient adherence to treatment due to fewer side effects.

Related News

Stock market today: Dow gains as Fed's favored inflation gauge cools

Sep 27, 2024, 2:45 PM

The market is looking to August's PCE print to calculate whether another jumbo cut is coming.

QQQ
COST
BMY

F.D.A. Approves a New Antipsychotic Drug

Sep 26, 2024, 6:47 PM

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

BMY